<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://sciencex2.org" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>neurology</title>
 <link>http://sciencex2.org/en/taxonomy/term/655</link>
 <description>The taxonomy view with a depth of 0.</description>
 <language>en</language>
<item>
 <title>Lightweight, open, mobile, cheaper MRI brain scanner prototype working in lab </title>
 <link>http://sciencex2.org/en/node/44417</link>
 <description>&lt;h3 class=&quot;field-label&quot;&gt;Description&lt;/h3&gt;
&lt;div class=&quot;content&quot;&gt;
   &lt;p&gt;Those giant, claustrophobic, tunnel forming magnets used for magnetic resonance imaging (MRI) in labs and hospitals look so last century! They are pricey and heavy, making MRI systems immobile and demanding to install. Any alternative? Yes by implementing the pre-polarized MRI concept introduced some 15 years ago:&lt;/p&gt;
&lt;p&gt;&amp;quot;Writing in the Journal of Magnetic Resonance, Vadim Zotev and colleagues report success in imaging a human brain using a different type of MRI system: lightweight, open, mobile and significantly cheaper.&lt;/p&gt;
&lt;p&gt;By dividing the functions of these large-field magnets between two sets of magnets with different characteristics, Zotev et al. have produced the prototype of a machine that would be smaller and more open, as well as being capable of performing magnetic resonance imaging and magnetoencephalography at the same time.&lt;/p&gt;
&lt;p&gt;Conventional MRI machines reconcile these different requirements by using magnets that are both powerful and homogeneous. But could the same effect be achieved by using two simpler magnets and switching between them? The first magnet, strong but relatively inhomogeneous, would polarize the sample, whereas the second, weak but highly homogeneous, would be optimized for collecting resonance signals. This concept, termed pre-polarized MRI, was originally introduced by Macovski and Conolly2 some 15 years ago, and has been pursued by several research teams since.&lt;/p&gt;
&lt;p&gt;Zotev et al. now report obtaining images of a living human brain using pre-polarization at 30 millitesla (mT) and image data collection at just 46 microT, a similar strength to that of Earth&#039;s magnetic field and about 30,000 times weaker than that of typical clinical MRI machines. Using such small magnetic fields means that the frequencies of the signals produced by the oscillating nuclear spins are similarly reduced from the usual radiofrequency range to around 2 kilohertz &amp;mdash; a frequency readily audible to the human ear (approximately three octaves above middle C).&amp;quot;&lt;/p&gt;
&lt;div class=&quot;og_rss_groups&quot;&gt;&lt;ul class=&quot;links&quot;&gt;&lt;li class=&quot;first last og_links&quot;&gt;&lt;a href=&quot;/en/node/13856&quot; class=&quot;og_links&quot;&gt;Biomedical Sciences and Biotechnology&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-source&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Source&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;div class=&quot;field-item&quot;&gt;&lt;p&gt;Klaas P. Pruessmann: Medical imaging: Less is more&lt;br /&gt;
Nature 455, 43-44 (4 September 2008) | doi:10.1038/455043a&lt;br /&gt;
&lt;a href=&quot;http://www.nature.com/nature/journal/v455/n7209/full/455043a.html&quot; title=&quot;http://www.nature.com/nature/journal/v455/n7209/full/455043a.html&quot;&gt;http://www.nature.com/nature/journal/v455/n7209/full/455043a.html&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Zotev et al.: Microtesla MRI of the human brain combined with MEG.&lt;br /&gt;
J Magn Reson. 2008 Sep;194(1):115-20.&lt;br /&gt;
&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/18619876?dopt=Abstract&amp;amp;holding=npg&quot; title=&quot;http://www.ncbi.nlm.nih.gov/pubmed/18619876?dopt=Abstract&amp;amp;holding=npg&quot;&gt;http://www.ncbi.nlm.nih.gov/pubmed/18619876?dopt=Abstract&amp;amp;holding=npg&lt;/a&gt;&lt;/p&gt;
&lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
</description>
 <comments>http://sciencex2.org/en/node/44417#comments</comments>
 <category domain="http://sciencex2.org/en/taxonomy/term/900">brain</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/1426">Clinical Research</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/2495">magnetic resonance imaging</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/1049">MRI</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/655">neurology</category>
 <group domain="http://sciencex2.org/en/node/13856">Biomedical Sciences and Biotechnology</group>
 <pubDate>Wed, 17 Sep 2008 15:13:20 -0700</pubDate>
 <dc:creator>Attila Csordas</dc:creator>
 <guid isPermaLink="false">44417 at http://sciencex2.org</guid>
</item>
<item>
 <title>Investigation of Harvard psychiatrists highlights inadequate regulation of commercially funded research in academic institutions</title>
 <link>http://sciencex2.org/en/node/25599</link>
 <description>&lt;h3 class=&quot;field-label&quot;&gt;Description&lt;/h3&gt;
&lt;div class=&quot;content&quot;&gt;
   &lt;p&gt;Joseph Biederman and Timothy E. Wilens, both Harvard professors of psychiatry, are under investigation for failing to report millions of dollars in &amp;quot;consultant fees&amp;quot; received from pharmaceutical companies over the past decade. Both professors received government research grants requiring disclosure of any additional research monies received. In addition, Harvard limits the amount of corporate funding for conducting clinical trials to $10K, so the researchers appear to be in violation of multiple regulations designed to limit potential conflicts of interest between publicly funded basic research and corporation-backed translational research.&lt;/p&gt;
&lt;p&gt;In addition to emphasizing the need to improve the execution of existing regulations, and possibly expand them further such as through the creation of a national research funding registry, news of the investigation also casts a cloud of doubt on the scientist&#039;s research. Dr. Biederman&#039;s research, for example, promotes the treatment of antipsychotic drugs in young children to treat bi-polar disorder. Both the disease, and its treatment, are controversial topics fraught with questions about the subject nature of diagnosis, concerns over the long-term effects of medication as well as possible developmental consequences.&lt;/p&gt;
&lt;div class=&quot;og_rss_groups&quot;&gt;&lt;ul class=&quot;links&quot;&gt;&lt;li class=&quot;first last og_links&quot;&gt;&lt;a href=&quot;/en/node/15121&quot; class=&quot;og_links&quot;&gt;Ethics in Science&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-source&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Source&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;div class=&quot;field-item&quot;&gt;&lt;p&gt;&lt;a href=&quot;http://www.nytimes.com/2008/06/08/us/08conflict.html?ref=health&quot; title=&quot;http://www.nytimes.com/2008/06/08/us/08conflict.html?ref=health&quot;&gt;http://www.nytimes.com/2008/06/08/us/08conflict.html?ref=health&lt;/a&gt;&lt;/p&gt;
&lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
</description>
 <comments>http://sciencex2.org/en/node/25599#comments</comments>
 <category domain="http://sciencex2.org/en/taxonomy/term/427">ethics</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/296">medicine</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/655">neurology</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/608">neuroscience</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/766">research funding</category>
 <group domain="http://sciencex2.org/en/node/13857">Future of neuroscience</group>
 <group domain="http://sciencex2.org/en/node/15121">Ethics in Science</group>
 <pubDate>Tue, 17 Jun 2008 19:10:13 -0700</pubDate>
 <dc:creator>Katy Armstrong</dc:creator>
 <guid isPermaLink="false">25599 at http://sciencex2.org</guid>
</item>
<item>
 <title>controlled study confirms high fat diet can effectively treat epilepsy in children</title>
 <link>http://sciencex2.org/en/node/17011</link>
 <description>&lt;h3 class=&quot;field-label&quot;&gt;Description&lt;/h3&gt;
&lt;div class=&quot;content&quot;&gt;
   &lt;p&gt;A study (to be published in June 2008) by a team of neurologists at the University College London recently completed the first randomized trial of a controversial high-fat diet that has been used to treat children with epilepsy. The study of 145 children confirmed that a high-fat diet is an effective treatment for epileptic seizures in children, reducing the frequency of seizures by up to 90%.&lt;/p&gt;
&lt;p&gt;This work provides solid evidence that &amp;quot; lays to rest the issue of &amp;lsquo;Does it really work or not?&amp;rsquo;&amp;quot; (1), according to Dr. Shlomo Shinnar, the director of the Comprehensive Epilepsy Management Center at the Montefiore Medical Center in the Bronx. Dr. Shlomo&#039;s comment addresses the fact that although high-fat diets have been used to treat epilepsy since the 1920s, it has previously been dismissed by many doctors as a &amp;quot;marginal alternative therapy&amp;quot; (1).&lt;/p&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-source&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Source&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;div class=&quot;field-item&quot;&gt;&lt;p&gt;1) Previewed in the NY Times: &lt;a href=&quot;http://www.nytimes.com/2008/05/06/health/research/06epil.html?_r=1&amp;amp;ref=science&amp;amp;oref=slogin&quot; title=&quot;http://www.nytimes.com/2008/05/06/health/research/06epil.html?_r=1&amp;amp;ref=science&amp;amp;oref=slogin&quot;&gt;http://www.nytimes.com/2008/05/06/health/research/06epil.html?_r=1&amp;amp;ref=science&amp;amp;oref=slogin&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Article will appear in The Lancet Neurology in June 2008: &lt;a href=&quot;http://www.elsevier.com/wps/find/journalaudience.cws_home/622235/description?navopenmenu=-2&quot; title=&quot;http://www.elsevier.com/wps/find/journalaudience.cws_home/622235/description?navopenmenu=-2&quot;&gt;http://www.elsevier.com/wps/find/journalaudience.cws_home/622235/description?navopenmenu=-2&lt;/a&gt;&lt;/p&gt;
&lt;/div&gt;
  &lt;/div&gt;
&lt;/div&gt;
</description>
 <category domain="http://sciencex2.org/en/taxonomy/term/2059">epilepsy</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/446">lifestyle medications</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/296">medicine</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/655">neurology</category>
 <category domain="http://sciencex2.org/en/taxonomy/term/608">neuroscience</category>
 <pubDate>Wed, 07 May 2008 13:14:29 -0700</pubDate>
 <dc:creator>Katy Armstrong</dc:creator>
 <guid isPermaLink="false">17011 at http://sciencex2.org</guid>
</item>
</channel>
</rss>
